Evaluation of Sacubitril/Valsartan Prescribing and Monitoring at a Veterans Affairs Hospital

Heart Failure (HF) readmissions is a burden to the patient, family and healthcare system. The PARADIGM-HF trial demonstrated that patients on maintenance doses of sacubitril/valsartan 97/103 mg twice daily experienced a reduction in cardiovascular mortality and heart failure hospitalizations compared with enalapril. The Veterans Affairs (VA) Pharmacy Benefit Management (PBM) criteria for use recommends that patients follow-up with a provider within two to four weeks of therapy initiation for serum potassium, renal function, and blood pressure monitoring, and to ensure dose titration to the target maintenance dose.

Source: Journal of Cardiac Failure - July 31, 2019 Category: Cardiology Authors: Inela Masic, Christina W. Quillian, Sue Kim Tags: 330 Source Type: research